Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board.
Immutep provides clinical update on 'efti' and confirms board appointment
September 14, 2022 Australian Biotech
Latest Video
New Stories
-
Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - - Latest News -
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - - Latest News -
Director pay rises across ASX healthcare sector, but gender balance remains uneven
February 16, 2026 - - Latest News -
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - - Latest News -
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News

